ProCE Banner Activity

How Risk of Recurrence in HR-Positive/HER2-Negative Early Breast Cancer Impacts Therapeutic Choices

Clinical Thought

An expert discusses the impact of risk of recurrence on treatment selection for patients with early‑stage hormone receptor–positive/HER2‑negative breast cancer.

Released: November 14, 2022

Expiration: November 13, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Contributing Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Dr. Joyce O’Shaughnessy answers healthcare professionals’ questions on biomarkers for neo/adjuvant therapy for early breast cancer, from Clinical Care Options (CCO)